Most treatments for Crohn's, an autoimmune disorder, are geared to suppress the immune response, but a new study demonstrates that stimulating innate immunity also is effective at improving symptoms in many patients with the intestinal disorder.

Researchers from Washington University School of Medicine in St. Louis, Massachusetts General Hospital and other institutions found that treatment with GM-CSF ( granulocyte macrophage colony stimulating factor ) alleviated symptoms of Crohn's disease and improved patients' quality of life. Patients who received the drug also had significantly less inflammation in the mucosal linings of their intestines.

" That's very significant," says first author Joshua R. Korzenik.. " We have clear, clinical evidence that patients feel better and have less pain and other problems related to Crohn's disease.
Endoscopic evidence also seems to demonstrate the drug helps with underlying inflammation."

Crohn's affects about half a million people in the United States.
A typical Crohn's disease patient deals with diarrhea, abdominal pain and intra-abdominal infections.
Frequently, scar tissue closes off sections of the intestine, and patients need surgery to eliminate those blockages.

Korzenik and co-principal investigator Brian K. Dieckgraefe, at Washington University, have been investigating the treatment of Crohn's disease by enhancing the body's innate immunity since the mid-1990s.

" The idea of priming the immune system in patients with Crohn's disease sounds a bit crazy at first," says Dieckgraefe. " But there are two types of immunity, and we're only dealing with half of the immune system. We're priming early immune cells, such as neutrophils and macrophages, not the T cells and B cells that are suppressed by other Crohn's disease therapies."

The strategy appears to help a significant number of patients.
In 2002, Korzenik and Dieckgraefe published results from a preliminary15-patient, open-label study in The Lancet reporting that GM-CSF treatment improved symptoms of Crohn's disease in the majority of patients with moderate to severe forms of the disorder.

In this larger, phase II clinical study, Korzenik, Dieckgraefe and a team of researchers from around the country followed 124 patients at 28 centers to determine whether GM-CSF, commercially known as Leukine ( Sagramostim ), would help patients with moderate to severe Crohn's disease.

In the study, 81 participants got daily injections of GM-CSF, which stimulates the activity of certain cells in the immune system. Another 43 received an inactive placebo. The investigators wanted to see whether patients on the drug would experience a decrease in the Crohn's Disease Activity Index ( CDAI ), which registers severity of Crohn's disease symptoms on a scale from one ( mild ) to 600 ( severe ).

After eight weeks of treatment, 48 percent of those who received GM-CSF had a 100-point improvement in their CDAI score. Only 26 percent of those who received the placebo had a similar improvement. In all, 40 percent of those who received the drug went into remission, compared to 19 percent of the placebo group. The researchers also measured quality of life with the Inflammatory Bowel Disease Questionnaire. Scores on that test range from a low of 32 to a high of 224. After eight weeks, scores improved an average of 28 points in the group receiving treatment, compared to a 16-point improvement in the placebo group.

There were minor side effects to treatment -- some patients developed soreness at the injection site or reported bone pain -- and a handful of more serious side effects, including migraines, weakness and lethargy. Dieckgraefe says it is important to remember that powerful medications can sometimes have serious side effects, so studies must continue to ensure GM-CSF is not used in patients it might harm.

The investigators believe if research continues to demonstrate the drug is effective and safe for most patients, using GM-CSF earlier in the course of Crohn's disease might be especially beneficial.

" Our study population included many people who were very sick: more than 80 percent of these patients already had been treated with steroids, and about 70 percent had been on some type of immune system inhibitor," Korzenik says. " Response rates might be higher in patients whose disease is milder and who haven't been on so many other treatments."

" And as we move forward, we'd like to learn whether improving symptoms now can improve long-term outcomes and prevent some of the abscesses, fistulas and surgeries that are so common in many Crohn's patients," Dieckgraefe adds.

Source: Washington University School of Medicine, 2005


XagenaMedicine2005